Microbot Medical Inc. (Nasdaq: MBOT) today announced the closing of its previously announced registered direct offering ...

(OTCQB: BIXT) (the "Company”), a clinical stage biotechnology company developing oral and intravenous drugs to treat viral diseases, fibrosis, stroke, dementia, and Alzheimer's disease, announced its ...

China's ETF market demonstrated exceptional performance in 2024, with notable returns and substantial growth in assets under ...

TAMPA BAY, FL, Jan. 10, 2025 (GLOBE NEWSWIRE) -- KnowBe4, the world-renowned cybersecurity platform that comprehensively addresses human risk management, today announced it has been named a winner for ...

Correcting & Replacing: Y-mAbs Therapeutics, Inc. is re-issuing in entirety its press release, originally issued on January 10, 2025 at 7:05 a.m. ET, to correct a scrivener's error in the presentation ...

THE Armed Forces of the Philippines (AFP) is doing background checks on candidates in the May elections to safeguard the ...

Driving Sustainability Through Streamlined Greenhouse-to-Grocer Operations; Aligning Technology with Company's Zero-Waste ...

"I am pleased to announce the completion of this important acquisition, bringing another well-established home energy ...

New Directors Bring Extensive Leadership Experience in Corporate Strategy and Commercialization. SEATTLE and VANCOUVER, ...

InflammX Therapeutics Inc., a clinical-stage biotechnology company focused on developing innovative therapies for retinal diseases with significant unmet needs, announced today that it has entered ...

Reports preliminary fourth quarter 2024 revenue in the range of approximately $19.2 million to $19.4 million Reports preliminary full-year 2024 revenue in the range of approximately $73.1 million to ...

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Jan. 10, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142, the ...